Sponsor: UroGen Pharma, Inc.
Sponsor Study ID: UT002
Study Title: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
CTO #: 104174
NCT Number: NCT06774131
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder
Study Objectives: To evaluate the tumor ablative effect of UGN-104, a novel formulation of UGN-101, in patients with LG-UTUC. To evaluate the durability of response with respect to DOR and DCR rate at scheduled disease assessment time points.